A ubiquitination assay demonstrated that mutation of IGF2BP3 at K213 could block Parkin‐mediated ubiquitination, reduce the oncogenic function of IGF2BP3 and inhibit cervical cancer cell proliferation (Figures 4 and 5). This evidence concerns the gene PRKN and cervical cancer.